The notes were offered at par. The offering is expected to close on or about June 1, 2018.
As previously announced, the company is seeking to amend and restate its existing credit agreement and borrow USD4.565 bn of new term B loans under the new credit agreement.
The proceeds of the notes and the new term B Loans, along with cash on hand, are expected to be used to refinance the company's outstanding term B loans and redeem the company's 5.375% senior notes due 2020, the issuer's 6.375% senior notes due 2020, the issuer's 6.75% senior notes due 2021, and the issuer's 7.25% senior notes due 2022, and to pay related fees and expenses.
Valeant Pharmaceuticals International is a multinational specialty pharmaceutical company that develops, manufactures and markets a broad range of pharmaceutical products primarily in the areas of dermatology, gastrointestinal disorders, eye health, neurology and branded generics.
TELA Bio launches LIQUIFIX for US hernia surgery
Cognizant and NVIDIA partner to revolutionize drug discovery with generative AI
Neupulse raises funds for Tourettes Syndrome wearable tech
Bonesupport gains FDA clearance for CERAMENT G in open fractures
Epitomee submits Weight Loss Capsule for FDA approval in US
Halma acquires Rovers Medical Devices
boston Scientific granted FDA approval for AGENT Drug-Coated Balloon